It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
Subscribe To Our Newsletter & Stay Updated
